Cargando…

Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment

An essential cytokine system for the osteoclast biology in multiple myeloma (MM) consists of the receptor of activator of NF-κB ligand (RANKL), its receptor (RANK), and the soluble decoy receptor, osteoprotegerin (OPG). Myeloma cells cause imbalance in OPG/RANKL interactions. We measured serum level...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sfiridaki, K., Pappa, C. A., Tsirakis, G., Kanellou, P., Kaparou, M., Stratinaki, M., Sakellaris, G., Kontakis, G., Alexandrakis, M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175728/ https://www.ncbi.nlm.nih.gov/pubmed/21941412 http://dx.doi.org/10.1155/2011/867576

Ejemplares similares

Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma
por: Sfiridaki, Aikaterini, et al.
Publicado: (2011)

Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients
por: Tsirakis, G., et al.
Publicado: (2011)

Coexistence of Plasma Cell Dyscrasia with Prefibrotic Stage of Primary Myelofibrosis: A Case Report
por: Tsirakis, George, et al.
Publicado: (2011)

Biology of RANK, RANKL, and osteoprotegerin
por: Boyce, Brendan F, et al.
Publicado: (2007)

Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma
por: Alexandrakis, Michael G., et al.
Publicado: (2013)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010)

RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes
por: Kondegowda, Nagesha Guthalu, et al.
Publicado: (2023)

Anemia in Heart Failure Patients
por: Alexandrakis, Michael G., et al.
Publicado: (2012)

Association of salivary RANKL and osteoprotegerin levels with periodontal health
por: Ochanji, A. A., et al.
Publicado: (2017)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL
por: Irtyuga, Olga, et al.
Publicado: (2017)

The association of osteoprotegerin and RANKL with osteoporosis: a systematic review with meta-analysis
por: Chi, Guanghao, et al.
Publicado: (2023)

Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study
por: Amer, Osama E., et al.
Publicado: (2022)

Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease
por: Krela-Kaźmierczak, Iwona, et al.
Publicado: (2015)

The impact of nonosteogenic factors on the expression of osteoprotegerin and RANKL during human fracture healing
por: Starlinger, Julia, et al.
Publicado: (2019)

Role of RANKL–RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications
por: Kohli, Sarvraj Singh, et al.
Publicado: (2011)

Serum, saliva, and GCF concentration of RANKL and osteoprotegerin in smokers versus nonsmokers with chronic periodontitis
por: Behfarnia, Parichehr, et al.
Publicado: (2016)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Erratum: Serum, saliva, and GCF concentration of RANKL and osteoprotegerin in smokers versus nonsmokers with chronic periodontitis
Publicado: (2016)

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases
por: Dutka, Mieczysław, et al.
Publicado: (2021)

Screening of osteoprotegerin-related feature genes in osteoporosis and functional analysis with DNA microarray
por: Wu, Xiaoming, et al.
Publicado: (2013)

Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis
por: Kurz, Katharina, et al.
Publicado: (2015)

Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits
por: Lv, You, et al.
Publicado: (2014)

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
por: Picarda, Gaëlle, et al.
Publicado: (2013)

Miliary tuberculosis with no pulmonary involvement in myelodysplastic syndromes: a curable, yet rarely diagnosed, disease: case report and review of the literature
por: Neonakis, Ioannis K, et al.
Publicado: (2008)

Marked Elevation in Plasma Osteoprotegerin Constitutes an Early and Consistent Feature of Cerebral Malaria
por: O’Regan, Niamh, et al.
Publicado: (2016)

Bone sparing effect of osteoprotegerin and anti-inflammatory cytokines in collagen-induced arthritis
por: de Vernejoul, M, et al.
Publicado: (2003)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

Mesenchymal stem cells inhibit RANK-RANKL interactions between osteoclasts and Th17 cells via osteoprotegerin activity
por: Cho, Kyung-Ah, et al.
Publicado: (2017)

Study of the incidence of osteoporosis in patients with Sjögren’s syndrome (pSS) and investigation of activation of the RANKL /RANK and osteoprotegerin (OPG) system
por: Skarlis, Charalampos, et al.
Publicado: (2018)

Distinct patterns of RANKL/osteoprotegerin system modulation through anti-tumour necrosis factor and corticosteroid therapy in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2005)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
por: Eid, Riham, et al.
Publicado: (2023)

Serum osteoprotegerin levels are related to height loss: The Tromsø Study
por: Jørgensen, Lone, et al.
Publicado: (2011)

P22: A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS OF THE ‘OL-ORAL’ STUDY
por: Katodritou, E, et al.
Publicado: (2022)

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males
por: Findlay, David, et al.
Publicado: (2008)

Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis
por: Goswami, Sudeshna, et al.
Publicado: (2015)

Effect of osteoprotegerin and pamidronate treatment in transgenic mice overexpressing human TNF
por: Redlich, K, et al.
Publicado: (2001)

Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease
por: Bolon, B, et al.
Publicado: (2001)

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma
por: Spanoudakis, E, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2aeu7tush6mctlj4icco8lr2rj